{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004974","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-07-29T11:00:20+00:00","discovered_at":"2026-07-29T11:05:00.286772+00:00","generated_at":"2026-07-29T11:06:14.905752+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands","bullets":["Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).","Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% YoY LC to >$1B; 2026 revenue outlook raised to ~$3.7B combined.","Acquired Emalex for ~$700M cash; NDA for ecopipam (Tourette) submitted; $726M expenses in Q2.","Generics revenues down 15% YoY LC due to lenalidomide competition; biosimilars on track for $800M by 2027.","ADS program replaced with ordinary shares on NYSE starting Sept 14, 2026; Fitch upgraded to BBB-."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004974","json":"https://secwatch.observer/filing/0001171843-26-004974.json","markdown":"https://secwatch.observer/filing/0001171843-26-004974.md","text":"https://secwatch.observer/filing/0001171843-26-004974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/0001171843-26-004974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/f8k_072926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:06:14.905752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}